Health CanadaGeneral Alert
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of...
Published: January 7, 2022Recall ID: 63799Category: generalCountry: Canada
Reason for Recall / Hazard
New safety information - COVID
Product Description & Identification
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
Affected Products
Casirivimab and Imdevimab
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63799 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/casirivimab-and-imdevimab-high-risk-treatment-failure-due-circulation-sars-cov-2 |
| Issue | New safety information - COVID |
| Title | Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant |
| Product | Casirivimab and Imdevimab |
| Archived | 0 |
| Category | Biologic or vaccine |
| Last updated | 2022-01-07 |
| Organization | Marketed health products |